Eton Pharmaceuticals (NASDAQ:ETON) Now Covered by B. Riley

B. Riley assumed coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research report report published on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $21.00 target price on the stock.

Several other equities analysts have also commented on ETON. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright upped their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, January 6th.

Eton Pharmaceuticals Trading Up 11.9 %

Shares of NASDAQ:ETON opened at $13.44 on Friday. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00. The stock’s 50-day moving average price is $11.64 and its two-hundred day moving average price is $7.35. The firm has a market cap of $350.13 million, a price-to-earnings ratio of -61.09 and a beta of 1.38.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth $420,000. Renaissance Technologies LLC boosted its position in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares during the period. Nantahala Capital Management LLC acquired a new stake in Eton Pharmaceuticals in the 2nd quarter valued at $3,095,000. Stonepine Capital Management LLC purchased a new position in Eton Pharmaceuticals in the second quarter valued at about $362,000. Finally, Aristides Capital LLC acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth about $658,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.